Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebola GP Vaccine Phase 1 Study
NCT02370589Phase 1Completed
- Sponsor
- Novavax
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Ebola virus disease (EVD) (13 arms), sponsored by Novavax. Primary endpoints: Assessment of Adverse Events, SAEs, Medically Attended Events and Significant New Medical Conditions and Immunogenicity as assessed by serum IgG antibody levels specific for EBOV Gp antigen. Started Feb 2015; status: completed.
02
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02370589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370589.